Concepedia
Statistics
Publications
16
Citations
666
H-Index
14
Active since
2017
Affiliations
Dana-Farber Cancer Institute(Current)
Harvard University
University of Michigan
University at Buffalo, State University of New York
University of California San Diego
Tyler S. Beyett is an author at Dana-Farber Cancer Institute specializing in pharmacology, medicine, and drug discovery.
Top concepts
MedicinePharmacologyDrug DiscoveryMedicinal ChemistryBiochemistryDrug DevelopmentNatural SciencesRadiation OncologyMolecular PharmacologyOncology
Publications per year
2017–2024
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer
Ciric To, Tyler S. Beyett, Jaebong Jang et al. · Nature Cancer · 2022 · 146 citations · Full text
Therapy-resistant Mutant Forms, Medicine, Pharmacology +9
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
Tyler S. Beyett, Ciric To, David E. Heppner et al. · Nature Communications · 2022 · 80 citations · Full text
Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
Emre Tkacik, Kunhua Li, Gonzalo L. González‐Del Pino et al. · Journal of Biological Chemistry · 2023 · 62 citations · Full text
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
Ikuko Nakamura, Shinji Kohsaka, Masachika Ikegami et al. · npj Precision Oncology · 2021 · 52 citations · Full text
Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKKε and Reveal Mechanisms for Selective Inhibition
Tyler S. Beyett, Xinmin Gan, Shannon M. Reilly et al. · Molecular Pharmacology · 2018 · 50 citations · Full text
1–5 of 16